IDRX-42

IDRX-42 is a potent, oral, highly selective small molecule tyrosine kinase inhibitor developed for the treatment of gastrointestinal stromal tumors (GIST) driven by KIT mutations. It is designed to inhibit both primary activating mutations (exons 9 and 11) and secondary resistance mutations (exons 13 and 17) in the KIT gene, which are common mechanisms of disease progression and resistance in GIST patients. IDRX-42 has demonstrated superior antitumor activity compared to current standard therapies such as imatinib and sunitinib in preclinical models. The drug has received Orphan Drug Designation and Fast Track Designation from the FDA for GIST after progression on or intolerance to imatinib. It is currently being evaluated as monotherapy in first-in-human Phase 1/1b clinical trials (StrateGIST 1), with plans for further development[1][5][6][8].

Other names

velzatinib